Design paperThe Childhood Asthma Management Program (CAMP): Design, Rationale, and Methods
Introduction
Asthma, the most common chronic respiratory disease of childhood, is characterized by airway obstruction that is at least partially reversible, by airway inflammation, and by increased airway responsiveness to a variety of stimuli [1]. Ten million children under the age of 16 in the United States have asthma [2]. Both its prevalence and the frequency of hospitalizations it necessitates are increasing among children 3, 4, 5. Asthma appears to have a strong inverse effect on lung growth in childhood [6]. The maximal level of lung function attained in early adulthood may be an important predictor of the rate of decline of lung function [7], which, in turn, may lead to the development of chronic obstructive lung disease.
Therapy for asthma focuses on prevention and/or treatment of airway inflammation, as well as relief of symptoms. Studies have found inhaled corticosteroids to relieve bronchial responsiveness and increase lung function 8, 9, 10. Nonsteroid anti-inflammatory medications have also been found effective in a substantial proportion of patients 11, 12, 13. Bronchodilators (such as inhaled β-agonists, inhaled anticholinergic agents, and oral theophylline) work quickly to relieve symptoms by relaxing the smooth muscles in the walls of the airways. Asthma episodes that do not respond sufficiently to bronchodilators may be treated with short courses (several days) of oral steroids. Concerns remain, however, about the long-term use of steroids in children, as they may decrease or delay somatic growth and sexual and bone maturation 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25. Repeated use of oral steroids to control acute exacerbations carries other side effects, such as adrenal suppression, osteoporosis, and cataracts 26, 27, 28.
The concerns about side effects, uncertainty about the relative effectiveness of steroid versus nonsteroid antiasthma medication, and questions about the need for chronic medication for mild asthma pose a dilemma for clinicians. With these issues in mind, the National Heart, Lung, and Blood Institute (NHLBI) released a Request for Proposal (RFP) for the Childhood Asthma Management Program (CAMP) in November 1990. The RFP called for proposals for a trial comparing regular use of two classes of anti-inflammatory medications (inhaled corticosteroids or cromolyn sodium) to regular bronchodilator medication. The NHLBI awarded contracts for the clinics and coordinating center in September 1991.
The investigators, the sponsor, and the trial’s Data and Safety Monitoring Board (DSMB) approved a protocol for a randomized, controlled clinical trial designed to determine the long-term efficacy and safety of three treatment strategies for mild to moderate asthma in children aged 5 to 12 years at enrollment 29, 30. Budesonide (Pulmicort, Astra USA, Inc.), an inhaled glucocorticoid, and nedocromil (Tilade, Rhone-Poulenc Rorer), an inhaled nonsteroid anti-inflammatory medication, are each being compared with placebo. Every patient uses albuterol (Ventolin, Glaxo Inc.), an inhaled short-acting β-agonist bronchodilator, as needed for asthma symptoms and signs or as a precaution prior to exercise. The planned follow-up period of 5 to 6 years allows most participants to initiate or complete their pubertal growth spurts, thus permitting assessment of the effects of treatments on growth and development. Randomization of patients began in December 1993 and concluded in September 1995; follow-up continues currently. This report describes the design of the trial, the rationale for the design choices, and the methods of the trial.
Section snippets
Study Medications
Until the late 1980s, oral theophylline, a bronchodilator that is used daily, was considered a first-line asthma therapy. Its use declined dramatically as the anti-inflammatory properties of inhaled glucocorticoids came to light. Concern over serious adverse side effects in children, the requirement for periodic blood sampling to help minimize the risk of overdose, and the risk of drug interactions with commonly prescribed medications precluded selection of theophylline as a study medication 31
Screening and Data Collection
CAMP designed selection criteria (Table 1) to enroll patients with mild to moderate asthma and to exclude patients who could not comply with the protocol. Eligibility assessment included medical history, spirometry, successful completion of a 28-day screening period with daily recording of asthma symptoms (Table 2), and measurement of airway responsiveness. Data collected for baseline measurements not directly related to eligibility assessment included a physical examination, allergen skin
Discussion
CAMP is designed to determine the long-term efficacy and safety of three treatment strategies for mild to moderate asthma in children aged 5 to 12 years at enrollment. The trial aims to answer questions about the long-term growth and development of children with mild to moderate disease. This focus dictated the choice of postbronchodilator FEV1 as the primary outcome measure. Use of postbronchodilator FEV1 rather than the prebronchodilator measure minimizes fluctuations due to diurnal variation
Acknowledgements
The Childhood Asthma Management Program is supported by Contracts NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, and 16052 with the National Heart, Lung, and Blood Institute.
References (80)
- et al.
Prevalence of asthma and health service utilization of asthmatic children in an inner city
J Allergy Clin Immunol
(1982) - et al.
A comparison of the effects of nedocromil sodium and beclomethasone dipropionate on pulmonary function, symptoms, and bronchial responsiveness in patients with asthma
J Allergy Clin Immunol
(1989) - et al.
Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children
Respir Med
(1994) - et al.
Evolving role of theophylline for treatment of chronic childhood asthma
J Pediatr
(1995) - et al.
Regular inhaled beta-agonist treatment in bronchial asthma
Lancet
(1990) - et al.
Effects of nedocromil sodium on in vitro induced migration, activation and mediator release from human granulocytes
J Allergy Clin Immunol
(1993) - et al.
Modulation by nedocromil sodium of immunologic and nonimmunologic activation of monocytes, macrophages, and platelets
J Allergy Clin Immunol
(1993) Effect of nedocromil sodium on mediator release from mast cells
J Allergy Clin Immunol
(1993)- et al.
Highlights of the nedocromil sodium clinical study presentations
J Allergy Clin Immunol
(1993) - et al.
Power and sample size calculationsa review and computer program
Controlled Clin Trials
(1990)